Patient presents with a history of melanoma, now exhibiting signs and symptoms concerning for metastatic disease.  Review of systems reveals patient complaints including fatigue, weight loss, and new or changing moles. Physical examination demonstrates palpable lymphadenopathy and or the presence of subcutaneous nodules.  Patient history includes a previous diagnosis of cutaneous melanoma, Breslow thickness documented as  (insert thickness) mm, Clark level (insert level), with or without ulceration, mitotic rate (insert rate), and positive or negative sentinel lymph node biopsy.  Imaging studies, such as CT scan, MRI, PET scan, and or X-ray, have been ordered or performed to assess for metastatic spread to distant sites including lung, liver, brain, bone, and soft tissue.  Laboratory tests, including complete blood count, liver function tests, and lactate dehydrogenase, are also being conducted to evaluate overall health status and aid in staging.  Differential diagnoses considered include other malignancies, infections, and benign conditions.  The patient's current presentation is consistent with stage III or stage IV metastatic melanoma based on the American Joint Committee on Cancer AJCC staging system.  Treatment plan discussion includes options such as immunotherapy, targeted therapy, chemotherapy, surgical resection, radiation therapy, and or palliative care, depending on the extent of metastatic disease and patient's overall health.  Referrals to oncology, dermatology, and or palliative care specialists have been made or are planned. Patient education provided regarding prognosis, treatment options, and potential side effects. Follow-up appointments are scheduled for ongoing monitoring and management of the metastatic melanoma.  Genetic testing for BRAF, NRAS, and other relevant mutations may be considered to guide personalized treatment strategies.  This documentation supports medical billing and coding using ICD-10 code C43.9 for malignant melanoma of unspecified site, along with appropriate codes for the specific metastatic sites and treatment modalities.